| DrugRepV_4747 | tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4748 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4749 | 1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4750 | sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4751 | tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4752 | sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4753 | 4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4754 | sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4755 | tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4756 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4757 | ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4758 | sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Middle East respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4759 | tert-butyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4760 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4761 | 1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4762 | sodium (2S)-1-hydroxy-2-[(2S)-2-({[(1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4763 | tert-butyl 4-benzyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4764 | sodium (2S)-2-[(2S)-2-{[({4-benzyl-1-[(tert-butoxy)carbonyl]piperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4765 | 4-benzyl-1-methanesulfonylpiperidin-4-yl N-[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4766 | sodium (2S)-2-[(2S)-2-({[(4-benzyl-1-methanesulfonylpiperidin-4-yl)oxy]carbonyl}amino)-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4767 | tert-butyl 4-ethyl-4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4768 | sodium (2S)-2-[(2S)-2-{[({1-[(tert-butoxy)carbonyl]-4-ethylpiperidin-4-yl}oxy)carbonyl]amino}-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4769 | ethyl 4-({[(1S)-3-methyl-1-{[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}butyl]carbamoyl}oxy)piperidine-1-carboxylate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |
| DrugRepV_4770 | sodium (2S)-2-[(2S)-2-[({[1-(ethoxycarbonyl)piperidin-4-yl]oxy}carbonyl)amino]-4-methylpentanamido]-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propane-1-sulfonate | NA | NA | Severe acute respiratory syndrome coronavirus | NA | NA | FRET protease assay | Decrease (50 %) | NA | 29544147 |